{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:10:01Z","timestamp":1787901001216,"version":"build-2784847793"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Amyloid light-chain (AL) amyloidosis is a hematological disorder characterized by abnormal proliferation of a plasma cell clone producing monoclonal free light chains that misfold and aggregate into insoluble fibrils in various tissues. Cardiac involvement is a common feature leading to restrictive cardiomyopathy and poor prognosis. Current first-line treatments aim at achieving hematological response by targeting the plasma cell clones, and these have been adapted from multiple myeloma therapy. Patients with AL amyloidosis often exhibit multiorgan involvement, making them susceptible to cancer therapy-related cardiovascular toxicity. Managing AL amyloidosis is a complex issue that requires enhanced knowledge of the cardio-oncological implications of hematological treatments. Future research should focus on implementing and validating primary and secondary prevention strategies and understanding the biochemical basis of oncological therapy-related damage to mitigate cardiovascular toxicity.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1212983","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T17:36:35Z","timestamp":1688578595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiovascular toxicity from therapies for light chain amyloidosis"],"prefix":"10.3389","volume":"10","author":[{"given":"Paolo","family":"Morfino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Chianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Maria","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"AL amyloidosis for cardiologists","volume":"4","author":"Wechalekar","year":"2022","journal-title":"JACC CardioOncology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: current chemotherapy and immune therapy treatment strategies","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2018.05.018","article-title":"Therapies for cardiac light chain amyloidosis: an update","volume":"271","author":"Aimo","year":"2018","journal-title":"Int J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","article-title":"Cardiovascular adverse events in modern myeloma therapy\u2014incidence and risks. A review from the European myeloma network (EMN) and Italian society of arterial hypertension (SIIA)","volume":"103","author":"Bringhen","year":"2018","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","article-title":"Global epidemiology of amyloid light-chain amyloidosis","volume":"17","author":"Kumar","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"B14","first-page":"665","article-title":"Amyloidosis (AL). clinical and laboratory features in 229 cases","volume":"58","author":"Kyle","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"QJM"},{"key":"B17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/bloodadvances.2020003782","article-title":"Prognostic restaging after treatment initiation in patients with AL amyloidosis","volume":"5","author":"Abdallah","year":"2021","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14797\/mdcvj.1070","article-title":"Light chain amyloidosis: epidemiology, staging, and prognostication","volume":"18","author":"Baker","year":"2022","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bjh.16436","article-title":"Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits","volume":"189","author":"Popkova","year":"2020","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/17474086.2022.2115353","article-title":"Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner\u2019s perspective","volume":"15","author":"Bomsztyk","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"key":"B26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/eurjpc\/zwaa034","article-title":"Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry","volume":"29","author":"Caro-Cod\u00f3n","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European society of cardiology in collaboration with the international cardio-oncology society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American heart association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of cardiotoxicity and validation of the heart failure association-international cardio-oncology society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a world health organization pharmacovigilance study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaccao.2021.11.002","article-title":"Healthy lifestyle benefits both cancer and cardiovascular disease","volume":"3","author":"Michos","year":"2021","journal-title":"JACC CardioOncology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/jcm10163731","article-title":"Statin use can attenuate the decline in left ventricular ejection fraction and the incidence of cardiomyopathy in cardiotoxic chemotherapy recipients: a systematic review and meta-analysis","volume":"10","author":"Kim","year":"2021","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the heart failure association (HFA), the European association of cardiovascular imaging (EACVI) and the cardio-oncology council of the European society of cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12185-015-1814-0","article-title":"Decrease of B-type natriuretic peptide to less than 200\u2005pg\/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis","volume":"102","author":"Ishiguro","year":"2015","journal-title":"Int J Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and Serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jcmg.2017.12.011","article-title":"Effect of traditional heart failure risk factors on myocardial dysfunction in adult survivors of childhood cancer","volume":"11","author":"Nolan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: a review","volume":"9","author":"Nicol","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B46","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome inhibitor-related cardiotoxicity: mechanisms. Diagnosis, and management","volume":"22","author":"Wu","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B49","year":""},{"key":"B50","year":""},{"key":"B51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1586\/ehm.11.39","article-title":"Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up","volume":"4","author":"Bhatia","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1038\/s41409-021-01427-2","article-title":"Cardiac complications associated with hematopoietic stem-cell transplantation","volume":"56","author":"Ohmoto","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11912-019-0774-6","article-title":"Cardiac complications in the adult bone marrow transplant patient","volume":"21","author":"Tuzovic","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3390\/jpm12111797","article-title":"Cardiovascular complications in hematopoietic stem cell transplanted patients","volume":"12","author":"Zhao","year":"2022","journal-title":"J Pers Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3109\/10428194.2014.926346","article-title":"Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma","volume":"56","author":"Gul","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31227","article-title":"Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation: lifestyle and heart disease after HCT","volume":"124","author":"Leger","year":"2018","journal-title":"Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/bmt.2013.192","article-title":"Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement","volume":"49","author":"Girnius","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B61","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.bbmt.2017.11.040","article-title":"Adverse prognostic factors for morbidity and mortality during peripheral blood stem cell mobilization in patients with light chain amyloidosis","volume":"24","author":"Yeh","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B62","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1753944712464102","article-title":"Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors","volume":"6","author":"Sureddi","year":"2012","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of cardiovascular risk in patients with multiple myeloma","volume":"9","author":"Plummer","year":"2019","journal-title":"Blood Cancer J"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor","volume":"68","author":"Goldberg","year":"1986","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"232470961348034","DOI":"10.1177\/2324709613480346","article-title":"Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management","volume":"1","author":"Dhesi","year":"2013","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B68","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.5772\/63467","article-title":"Proteasome inhibitors to treat AL amyloidosis","volume-title":"Exploring new findings on amyloidosis","author":"Driscoll","year":"2016"},{"key":"B70","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejphar.2018.09.014","article-title":"Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects","volume":"838","author":"Gavazzoni","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00277-018-3238-4","article-title":"Risk of adverse events associated with front-line anti-myeloma treatment in medicare patients with multiple myeloma","volume":"97","author":"Chen","year":"2018","journal-title":"Ann Hematol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"101536","DOI":"10.1016\/j.cpcardiol.2022.101536","article-title":"Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy","volume":"48","author":"Zheng","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"341","DOI":"10.33549\/physiolres.931005","article-title":"Distribution and interrelationship of ubiquitin proteasome pathway component activities and ubiquitin pools in various porcine tissues","volume":"56","author":"Patel","year":"2007","journal-title":"Physiol Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","article-title":"Cardiovascular complications of proteasome inhibitors used in multiple myeloma","volume":"26","author":"Cole","year":"2018","journal-title":"Cardiol Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","article-title":"Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1002\/ajh.24599","article-title":"Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: a propensity matched study of 1,790 patients: cardiotoxicity risk with bortezomib","volume":"92","author":"Reneau","year":"2017","journal-title":"Am J Hematol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12185-010-0586-9","article-title":"Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma","volume":"91","author":"Takamatsu","year":"2010","journal-title":"Int J Hematol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1365-2141.2007.06659.x","article-title":"Unexpected cardiotoxicity in haematological bortezomib treated patients","volume":"138","author":"Orciuolo","year":"2007","journal-title":"Br J Haematol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000340050","article-title":"Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature","volume":"128","author":"Bockorny","year":"2012","journal-title":"Acta Haematol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma: bortezomib for relapsed or refractory multiple myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e87671","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. Moretti C, curatore","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1182\/blood.V122.21.3187.3187","article-title":"Quantifying the risk of heart failure associated with proteasome inhibition: a retrospective analysis of heart failure reported in phase 2 and phase 3 studies of bortezomib (btz) in multiple myeloma (MM)","volume":"122","author":"Laubach","year":"2013","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.clml.2012.06.002","article-title":"Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma","volume":"12","author":"Bruce","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B88","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"B90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"\u2018Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma\u2014analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur J Haematol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1871529X21666210412113017","article-title":"Incidence and management of carfilzomib-induced cardiovascular toxicity; a systematic review and meta-analysis","volume":"21","author":"Latif","year":"2021","journal-title":"Cardiovasc Hematol Disord-Drug Targets"},{"key":"B95","doi-asserted-by":"publisher","first-page":"134","DOI":"10.37616\/2212-5043.1311","article-title":"Carfilzomib-induced cardiotoxicity: an analysis of the FDA adverse event reporting system (FAERS)","volume":"34","author":"Buck","year":"2022","journal-title":"J Saudi Heart Assoc"},{"key":"B96","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers15030955","article-title":"Carfilzomib-based regimen and cardiotoxicity in multiple myeloma: incidence of cardiovascular events and organ damage in carfilzomib-dexamethasone versus carfilzomib-lenalidomide-dexamethasone. A real-life prospective study","volume":"15","author":"Astarita","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"107071","DOI":"10.1016\/j.rmed.2022.107071","article-title":"Etiology of pulmonary hypertension in multiple myeloma: a case series and literature review","volume":"206","author":"Desmarais","year":"2023","journal-title":"Respir Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib\u2013dexamethasone versus physician\u2019s choice in relapsed or refractory AL amyloidosis","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"key":"B101","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ajh.26866","article-title":"Quality of life and symptoms among patients with relapsed\/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician\u2019s choice","volume":"98","author":"Sanchorawala","year":"2023","journal-title":"Am J Hematol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2019-126023","article-title":"A phase 1\/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis","volume":"134","author":"Sanchez","year":"2019","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bcp.15499","article-title":"Cardiovascular complications of modern multiple myeloma therapy: a pharmacovigilance study","volume":"89","author":"Al-Yafeai","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bjh.14970","article-title":"Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma","volume":"180","author":"Fradley","year":"2018","journal-title":"Br J Haematol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0002-9343(77)90870-1","article-title":"The conduction system in cardiac amyloidosis","volume":"62","author":"Ridolfi","year":"1977","journal-title":"Am J Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hon.2959","article-title":"Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials","volume":"40","author":"Das","year":"2022","journal-title":"Hematol Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bjh.17685","article-title":"Lenalidomide and dexamethasone in relapsed\/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up","volume":"195","author":"Basset","year":"2021","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1182\/blood-2010-09-305136","article-title":"Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis","volume":"116","author":"Tapan","year":"2010","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"Am J Hematol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"B114","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/bjh.12152","article-title":"Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study","volume":"160","author":"Rosovsky","year":"2013","journal-title":"Br J Haematol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/00063030-200115030-00003","article-title":"Thalidomide in cancer: potential uses and limitations","volume":"15","author":"Singhal","year":"2001","journal-title":"BioDrugs"},{"key":"B117","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone\u2009\u00b1\u2009thalidomide for systemic light-chain amyloidosis: results of a phase II trial: risk-adapted ASCT\u2009+\u2009thal\/dex for AL amyloidosis","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"B119","year":"2016"},{"key":"B120","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"key":"B121","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/bjh.16401","article-title":"Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis","volume":"189","author":"Cohen","year":"2020","journal-title":"Br J Haematol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/13506129.2020.1767566","article-title":"Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients","volume":"27","author":"Milani","year":"2020","journal-title":"Amyloid"},{"key":"B124","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond","volume":"270","author":"Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"B125","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12935-022-02635-6","article-title":"Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis","volume":"22","author":"Sun","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-143180","article-title":"A phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated AL amyloidosis (SWOG S1702; NCT#03499808)","volume":"136","author":"Parker","year":"2020","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.clml.2018.08.021","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone for treatment-resistant immunoglobulin light chain amyloidosis with multiple myeloma","volume":"19","author":"Iqbal","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B132","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1212983\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T17:36:42Z","timestamp":1688578602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1212983\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":132,"alternative-id":["10.3389\/fcvm.2023.1212983"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1212983","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"article-number":"1212983"}}